News | January 28, 2009

Fluorescent Proteins to Transform Biomedical Research

January 28, 2009 - Scientists at the Albert Einstein College of Medicine of Yeshiva University say that remarkable new tools, which spotlight individual cellular molecules, are helping advance biomedical research.

They have revealed that these new tools are photoactivatable fluorescent proteins (PAFPs) and other advanced fluorescent proteins (FPs).

Dr. Vladislav Verkhusha, associate professor of anatomy and structural biology at Einstein, says that PAFPs and FPs help noninvasively visualize the structures and processes in living cells at the molecular level.

The researcher says that it is now possible to follow cancer cells as they seek out blood vessels and spread throughout the body or to watch how cells manage intracellular debris, preventing premature aging.

The significance of this study lies in the fact that the new fluorescent proteins add considerably to the biomedical imaging revolution started by the 1992 discovery that the gene for a green fluorescent protein (GFP) found in a jellyfish could be fused to any gene in a living cell.

When the target gene is expressed, GFP lights up (fluoresces), creating a visual marker of gene expression and protein localization, via light (optical) microscopy.

While earlier technique could capture images only in non-living cells, the addition of PAFPs, more versatile versions of FPs, made it possible to do real-time SR fluorescence microscopy in living cells.

Dr. Verkhusha is said to have developed a variety of PAFPs and FPs for use in imaging mammalian cells, expanding the applications of fluorescence microscopy.

The collection includes PAFPs that can be turned on and off with a pulse of light, FPs that can fluoresce in different colors, and FPs that have better resolution for deep-tissue imaging.

The researcher most recently developed a red PAFP called PAmCherry1, which has faster photoactivation, improved contrast, and better stability compared to other PAFPs of its type.

"PAmCherry1 will allow improvements in several imaging techniques, notably two-color SR fluorescence microscopy, in which two different molecules or two biological processes can be viewed simultaneously in a single cell," Nature Methods quoted the researcher as saying in its online version.

Dr. Verkhusha's PAFPs have been used in several studies, providing new insights into a variety of biological processes.

In one of the studies, his PAFPs were used to capture the first nanoscale images of the orientation of molecules within biological structures.

"Such images could be useful in studying protein-protein interactions, the growth and collapse of intracellular structures, and many other biological questions," says Dr. Verkhusha.

In another study, Dr. Verkhusha contributed a novel PAFP to a new method of viewing individual breast cancer cells for several days at a time, providing new details on how cancer cells invade surrounding tissue and reach blood vessels, a process called metastasis.

"Mapping the fate of tumor cells in different regions of a tumor was not possible before the development of the photoswitching technology," explained John Condeelis, Ph.D., co-chair and professor of anatomy and structural biology and co-director of the Gruss Lipper Biophotonics Center.

Dr. Verkhusha has also developed new types of fluorescent proteins for use in conventional fluorescent microscopy, called fluorescent timers (FTs), which can change their color from blue to red over a matter of hours.

"These FTs will enable scientists to study the trafficking of cellular proteins and to provide accurate insight into the timing of intracellular processes, such as activation or inhibition of gene expression or protein synthesis," he says.

With the use of the FTs, he and his colleagues have shown for the first time how a protein called LAMP-2A, which scavenges cellular debris, is transported to intracellular organelles called lysosomes, where the debris is digested.

The researchers are of the opinion that understanding this process, which maintains the health of cells and organs, may lead to treatments to keep elderly people's organs in prime condition. (ANI)

Source: Yahoo at www.in.news.yahoo.com

For more information: www.aecom.yu.edu

Related Content

Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages